Truist initiated coverage of Chemours (CC) with a Buy rating and $27 price target The firm believes Chemours is positioned for “significant” earnings growth in 2025 and 2026 driven by continued growth at accretive margins for its next-generation refrigerant Opteon franchise. Consensus estimates are overly conservative regarding the potential for earnings recovery in the recently underperforming TiO2 segment, the analyst tells investors in a research note. Truist sees upside to the stock’s current valuation as the new management team implements its plans to optimize the company’s cost structure and target growth in higher-value product applications.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CC:
- Chemours price target lowered to $21 from $22 at Mizuho
- Chemours Appoints Google Executive to Board of Directors
- Chemours names Google executive Joseph Kava to board of directors
- Chemours Company Reduces Loan Margin for Cost Efficiency
- PCC Group to build chlor-alkali facility on Chemours Dallas TiO2 plant grounds